ERBB3 and breast cancer: Specifically, Sergina et al. observed that a cell membrane HER3 is upregulated in persistent BC cells after treatment with HER-family TKI, and that HER3-targeting siRNA could enhance susceptibility to EGFR-TKI in these cells [28].